AI Contributes to Early Detection of Clinically Relevant Breast Cancer
THURSDAY, Feb. 13, 2025 -- Artificial intelligence (AI) contributes to early detection of clinically relevant breast cancer, according to a study published online Feb. 3 in The Lancet Digital Health.
Veronica Hernström, M.D., from Lund University in Sweden, and colleagues conducted a randomized, controlled, parallel-group, noninferiority trial within the Swedish national screening program involving women recruited at four screening sites who were eligible for mammography screening. Participants were randomly assigned to AI-supported screening, which was used to triage screening examinations to single or double reading, or to standard double reading.
The researchers found that AI-supported screening among 53,043 participants resulted in 338 cancers detected and 1,110 recalls, while standard screening among 52,872 participants resulted in 262 cancers detected and 1,027 recalls. Cancer detection rates were 6.4 and 5.0 per 1,000 screened participants in the intervention and control groups (ratio, 1.29), respectively. AI-supported screening yielded increased detection of invasive cancers (270 versus 217; proportion ratio, 1.24), which were mostly small lymph node-negative cancers. There was also an increased detection of in situ cancers with AI-supported screening (68 versus 45; proportion ratio of 1.51); about half of the increased detection was high-grade in situ cancer. Compared with the control group, the intervention group had significantly higher positive predictive value of recall, with a ratio of 1.19. There were 61,248 and 109,692 screen readings in the intervention and control groups, respectively, resulting in a 44.2 percent reduction in the screen-reading workload.
"The use of AI did not negatively influence the rates of recalls, false positives, or consensus meetings and the screen-reading workload was reduced by almost half," the authors write.
One author disclosed ties to the pharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Features of Immunesenescence Present in Early Stages of Rheumatoid Arthritis
THURSDAY, Sept. 11, 2025 -- Some features of immunesenescence are present in the very early stages of rheumatoid arthritis (RA), according to a study published online Sept. 3 in...
Urine Biomarker Panel Sensitive, Specific for Prostate Cancer Diagnosis
THURSDAY, Sept. 11, 2025 -- A urine-based biomarker panel has high accuracy for diagnosing prostate cancer (PCa), according to a study published in the September issue of...
Hospitals Vary in Their Definition of Blood Culture Contamination
THURSDAY, Sept. 11, 2025 -- U.S. hospitals vary in how they define blood culture contamination (BCC), according to a study published online July 11 in the Journal of Clinical...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.